Your session is about to expire
← Back to Search
Oregovomab + Niraparib for Ovarian Cancer
Study Summary
This trial is testing if a new combination of drugs can help people with ovarian cancer that has come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 11 Patients • NCT01959672Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had up to 3 treatments for my cancer, including a platinum-based one, due to it getting worse or side effects.I am able and willing to sign a consent form for treatment.I have an autoimmune disease and am on immune suppressive therapy.I cannot use certain emergency drugs due to my medication.I haven't had major surgery in the last 3 weeks and have recovered from any surgery effects.I am allergic to mouse proteins or have had reactions to specific cancer drugs.I have chronic hepatitis B but it's under control with treatment.I haven't taken any colony-stimulating factors in the last 4 weeks.I have a known immune system condition, but not HIV.I have high-grade ovarian, fallopian tube, or peritoneal cancer that came back after responding to initial chemotherapy for at least 6 months.I have never been diagnosed with MDS or AML.I have had severe blood-related side effects from my last chemotherapy that lasted more than 4 weeks.I am able to care for myself and perform daily activities.My doctor believes I can live 6 more months and can pause cancer treatment for 12 weeks.I do not have brain or spinal cord cancer that is causing symptoms.I can take pills by mouth.Your blood test showed high levels of CA125 within the past 28 days.I've had radiation on more than 20% of my bone marrow in the last 2 weeks.My blood tests show my organs are functioning well.I haven't had any cancer besides non-melanoma skin cancer or cervical cancer in situ in the last 5 years.I have been on corticosteroids for more than 5 days, not counting inhalers or planned tapers.I have not had a heart attack in the last year and do not have severe heart or lung conditions.I don't have any serious uncontrolled health issues or infections.I have not had a blood transfusion in the last 2 weeks.I have been treated with oregovomab before.I had platinum-based chemo for ovarian cancer and responded well for 6+ months.I am HIV positive but my viral load is undetectable due to effective treatment.I am on long-term medication to suppress my immune system.My cancer is ovarian, fallopian tube, or peritoneal and has returned.I have hepatitis C that hasn't been treated or is currently being treated with an undetectable viral load.My cancer can be measured and tracked using scans.
- Group 1: Combination of Oregovomab and Niraparib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are enrolled in the experiment?
"CanariaBio Inc., the sponsor, requires 10 eligible participants in order to successfully carry out this trial. These individuals may be recruited from two locations: University of Virginia Health System (Charlottesville, VA) and Stephenson Cancer Center-University of Oklahoma Health Sciences Centre (Oklahoma City)."
Is this research endeavor still seeking participants?
"This clinical trial is actively seeking participants, as reported on clinicaltrials.gov. The post was initially made on the 25th of July 2022 and has been recently amended on the 26th of July 2022."
What criteria must a person meet to be eligible for this clinical trial?
"To be eligible for the trial, participants must possess a uterus and reside between 18-99 years old. 10 individuals are being welcomed into this research endeavour."
Is eligibility for this trial restricted to individuals under the age of 45?
"The eligibility conditions of this medical trial require participants to be between 18 and 99 years old. There are 175 studies for individuals under the age of majority, as well as 1399 research programs available to those over 65."
Has the regulatory body sanctioned Oregovomab for public use?
"While there is evidence of Oregovomab's safety, a score of 2 was attributed as this Phase 2 trial has yet to demonstrate its efficacy."
Share this study with friends
Copy Link
Messenger